Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis. Bandari DS, Sternaman D, Chan T, Prostko CR, Sapir T J Manag Care Pharm. 2012 Dec; 18(9):1-17. PMID: 23206263. Abstract CommentRecommendBookmarkWatch